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Impaired expression of protein phosphatase
2A subunits enhances metastatic potential of
human prostate cancer cells through
activation of AKT pathway
P Pandey1,4, P Seshacharyulu1,4, S Das1, S Rachagani1, M P Ponnusamy1, Y Yan2, S L Johansson2,3, K Datta1,2,
M Fong Lin1,2 and S K Batra*,1,2
1

Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198-5870, USA;
Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA and
3
Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA
2

Background: Protein phosphatase 2A (PP2A) is a dephosphorylating enzyme, loss of which can contribute to prostate cancer (PCa)
pathogenesis. The aim of this study was to analyse the transcriptional and translational expression patterns of individual subunits
of the PP2A holoenzyme during PCa progression.
Methods: Immunohistochemistry (IHC), western blot, and real-time PCR was performed on androgen-dependent (AD) and
androgen-independent (AI) PCa cells, and benign and malignant prostate tissues for all the three PP2A (scaffold, regulatory,
and catalytic) subunits. Mechanistic and functional studies were performed using various biochemical and cellular techniques.
Results: Through immunohistochemical analysis we observed significantly reduced levels of PP2A-A and -B0 g subunits (Po0.001
and P ¼ 0.0002) in PCa specimens compared with benign prostate. Contemporarily, there was no significant difference in PP2A-C
subunit expression between benign and malignant tissues. Similar to the expression pattern observed in tissues, the endogenous
levels of PP2A-A and B0 g subunits were abrogated from the low metastatic to high metastatic and AD to AI cell line models,
without any change in the catalytic subunit expression. Furthermore, using in vitro studies we demonstrated that PP2A-Aa scaffold
subunit has a role in dampening AKT, b-catenin, and FAK (focal adhesion kinase) signalling.
Conclusion: We conclude that loss of expression of scaffold and regulatory subunits of PP2A is responsible for its altered function
during PCa pathogenesis.

Prostate cancer (PCa) is the second leading cause of cancer-related
death among men in United States after lung cancer. In 2012, the
estimated number of new cases and deaths caused by PCa are
241 740 and 28 170, respectively (Siegel et al, 2012). A majority of
PCa patients are older men (over 65 years) and the disease is rarely
seen in younger men (below 40 years) (Hankey et al, 1999). The
median age for PCa diagnosis and death is 67 and 81 years,

respectively (Hoffman, 2011). The growth of PCa remains
androgen-dependent (AD) in its initial stage. Hence, during the
AD state, androgen deprivation therapy (ADT) leads to regression
of the locally advanced PCa (Chuu et al, 2011). When PCa relapses
after ADT, the disease progresses to an androgen-independent (AI)
state and eventually hormone-refractory disease develops (Sharifi
et al, 2005), which does not effectively respond to the existing
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therapeutic strategies. Many oncogenes and tumour suppressor
genes have been thoroughly investigated and they provide credence
to the idea that alteration of their normal physiological actions and
regulations can have an adverse impact on gene expression, resulting in various diseases including cancer. Genome-wide expression
profiling and pathway prediction associates a number of up- and
downregulated genes with cancer progression. Many candidate
tumour suppressor genes like Rb, p53, PTEN, CDKN2A, TP73,
ICAM1, SOCS1/2, SPRY2, PPP2CA, and PPP3CA have been shown
to be downregulated in cancer, whereas many proto-oncogenes
such as AKT, PKC, mTOR, c-fos, c-jun, HGF, KRAS, MET, and
EGFR have been shown to be upregulated (Singh et al, 2008).
Uncontrolled cell growth, metabolism, proliferation, migration,
and motility of cancer cells are regulated by various kinases and
phosphatases (Cohen, 2001). Protein phosphatase 2A (PP2A) is
highly conserved across a variety of eukaryotic species and
accounts for as much as 1% of the total cellular protein (Wera
and Hemmings, 1995). Protein phosphatase 2A is one of the major
serine threonine phosphatases and structurally it is composed of
three subunits: catalytic (C), scaffold (A), and regulatory (B)
subunit, with functional variability (Zhang and Claret, 2012).
Protein phosphatase 2A exists in two different forms: core enzyme
and holoenzyme (Kremmer et al, 1997). The core enzyme is
composed of the scaffold subunit (PP2A-A) and the catalytic
subunit (PP2A-C) and is present in the heterodimeric form. The
spatial and temporal diversity of this enzyme is provided by
the regulatory subunit (Virshup and Shenolikar, 2009) and it
interacts with the heterodimeric core enzyme to form the
heterotrimeric holoenzyme. The PP2A holoenzyme exists in
soluble form and gets compartmentalised in the cytosol, nucleus,
mitochondria, cytoskeleton, and organelle membranes (Inagaki
et al, 1994). Both the PP2A scaffold and the catalytic subunit exist
in two different isoforms a and b, among which a form is
predominant in nature. The regulation of PP2A activity mainly
relies on the regulatory B subunit, which determines substrate
selectivity, subcellular localisation, and regulates the catalytic
activity in a wide range of biological processes (Yang et al, 2003;
Yang and Phiel, 2010). The regulatory subunit is complex and
diverse in nature and constitutes four different families: B (B55/
PR55), B0 (B56/PR61), B00 (PR48/PR72/PR130), and B000 (PR93/
PR110). To provide further complexity, each member of the
regulatory subunit is subdivided into various isoforms like a, b, g,
d, and e (Kamibayashi et al, 1994; Shi, 2009).
Chen et al (2004) have demonstrated that suppression of a
specific regulatory subunit PP2A-B0 g is sufficient for human
cellular transformation by displacing PP2A-B0 g from the AC dimer
altering the PP2A-specific phosphatase activity in human embryonic kidney epithelial cells (Chen et al, 2004). Somatic alterations of
PP2A-Aa, Ab, and B0 g are associated with breast, lung and
colorectal cancer, and soft tissue sarcomas (Wang et al, 1998;
Ruediger et al, 2001; Esplin et al, 2006; Perrotti and Neviani, 2008;
Grochola et al, 2009). Functional haploinsufficiency of PP2A-Aa or
loss of PP2A-Aa are defective in binding with B0 g, resulting in
complete loss of hetrotrimeric complex formation, eventually
leading to cellular transformation (Chen et al, 2005), thus
supporting the tumour suppressor nature of PP2A (Mumby,
2007). In addition, earlier reports of Cho et al (2007) and Xu et al
(2006) have explained about the holoenzyme interaction of PP2AA/PP2A-C with the specific regulatory B subunit B56g. Protein
phosphatase type 2A has an important role in DNA replication,
cell cycle, signal transduction, and cytoskeleton dynamics (Janssens
and Goris, 2001). It positively regulates apoptosis and negatively
regulates the mitogenic pathway, suggesting that loss of it might be
involved in cancer development and progression (Perrotti and
Neviani, 2008). In various malignancies, such as lung, breast,
colon, gastric, and leukaemia, it has been shown that PP2A is
downregulated and its role in transformation clearly defines PP2A
www.bjcancer.com | DOI:10.1038/bjc.2013.160
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as a tumour suppressor gene (Westermarck and Hahn, 2008).
In prostate epithelia, various growth factors, receptors, and
androgens coordinately regulate cell proliferation by altering the
equilibrium between phosphorylation and dephosphorylation.
Studies have shown that the post-translational modifications of
the androgen receptor, such as active phosphorylation, facilitates
androgen-binding capacity and aids in the activation of the DNAbinding domain during transformation (Brinkmann, 2001).
Previous studies have shown that the androgen receptor is
regulated by phosphorylation and dephosphorylation. Insufficient
dephosphorylation of the androgen receptor leads to continuous
activation of the androgen receptor and enhances the androgen
receptor-mediated signalling pathways.
The aim of this study was to elucidate the expression pattern at
transcriptional and translational level of the scaffold, catalytic and
regulatory subunits of PP2A in AD and AI PCa cells, and in benign
and cancerous tissues. The methods in this study included
immunohistochemical analysis, quantitative real-time PCR, and
western blot assay to investigate the expression pattern of PP2A
subunits in PCa progression. Furthermore, we extended our study
by knocking down of PP2A scaffold subunit to identify whether
the loss of PP2A scaffold subunit expression may be one of the
mechanisms contributing to PCa progression. Overall, our results
suggest that even if there is no significant change in the expression
level of the catalytic subunit of PP2A, the differential expression or
loss of expression of the scaffold and regulatory subunits may lead
to altered function during the pathogenesis of PCa.
MATERIALS AND METHODS

Cell culture. Human PCa cell lines were obtained from various
sources: LNCaP cells having passage number less than 33 were
designated as clone 33 (C-33), which are generally AD cells, and
more than 80 passaged cells were designated as clone 81 (C-81, AI)
(Igawa et al, 2002; Singh et al, 2008), PC-3 (low metastatic, AI)
cells were obtained from the American Type Culture Collection
(Manassas, VA, USA) and PC-3M (AI), a highly metastatic subline
derived from liver metastasis of PC-3 cells, was obtained from
Dr Fidler University of Texas MD Anderson Cancer Center,
Houston, TX, USA. (Stephenson et al, 1992). PC-3 and PC-3M cell
lines were maintained in RPMI 1640 culture medium containing
10% fetal bovine serum (FBS) and antibiotics (100 mg ml ÿ 1
penicillin and streptomycin) and LNCaP C-33 and C-81 cells
were grown in RPMI 1640 culture medium supplemented with 5%
FBS and antibiotics (penicillin and streptomycin 100 mg ml ÿ 1). All
cell lines were grown at 37 1C with 5% CO2 in a humidified
atmosphere and media were changed every other day.
Antibodies and transfection reagents. The antibodies used are
very specific for three different subunits. Protein phosphatase 2A
catalytic subunit (catalogue no. 1512-s; Epitomic, Burlingame, CA,
USA) reacts to both a- and b-isoform of catalytic subunit.
The antibody does not crossreact among other family members of
PP2A subunits. Antibody directed against PP2A-A scaffold subunit
(81G5 rabbit monoclonal antibody, catalogue no. 2041-s; Cell
Signalling Technology, Danvers, MA, USA) detects both a- and
b-isoform of PP2A scaffold subunit. Protein phosphatase
type 2A-B56-g antibody (H-40, rabbit polyclonal, catalogue no.
SC67038; Santa Cruz Biotechnology, Santa Cruz, CA, USA)
recognises the epitope corresponding to amino acids 431–470
near the C terminus of PP2A-B56-g. Other antibodies used
for signalling studies include: phospho-AKT, total AKT, active
b-catenin, phospho-FAK (focal adhesion kinase) (Y576/577), total
FAK, and b-actin (obtained from Cell Signalling). Horseradish
peroxidase-coupled anti-mouse and anti-rabbit IgG secondary
antibodies, and enhanced chemiluminescence reagent was
2591
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purchased from Amersham Biosciences (Buckinghamshire, UK).
Transient transfection was performed using Lipofectamine 2000
reagent (Invitrogen, Carlsbad, CA, USA). Two small-interfering
RNA (siRNA) oligos targeted against human PP2A-Aa
(PPP2R1A), NM 014225 (Si-1 ‘50 -AGGCGGAACUUCGACAG
UA-30 ’ and Si-2 ‘50 -AAACUUAACUCCUUGUGCA-30 ’) and
scramble (SCR) oligo were purchased from Thermo Scientific
Dharmacon (Lafayette, CO, USA) and were used for the transient
knockdown study.
Immunohistochemistry analysis. Prostate tissue array having
normal prostate tissues and multiple PCa (Gleason grade 6–10)
tissue spots were obtained from Biomax (Bethesda, MD, USA).
First, the paraffin-embedded TMA arrays were deparaffinised
in xylene for 4  10 min, each followed by rehydration through
graded ethanol. Endogenous peroxidase was blocked using 3%
hydrogen peroxide for 30 min. Antigen retrieval was accomplished
using 0.01M preheated citrate buffer (pH ÿ 6.0, 90 1C) for 15 min
and was allowed to cool at room temperature. The slides were then
washed with phosphate-buffered saline (PBS) 2  5 min each.
Binding of nonspecific proteins were blocked by incubating the
tissue slides with 2.5 U horse serum (ImmPRESS kit; Vector Labs,
Burlingame, CA, USA) for 2 h. The sections were incubated
overnight at 4 1C with primary antibodies, PP2A-C (1 : 500), PP2AAa/b (1 : 50), and PP2A-B0 g (1 : 75) diluted in PBS. Slides were then
washed with PBS 4  10 min and incubated with the appropriate
secondary antibody (peroxidase-labelled, universal anti-mouse/
anti-rabbit IgG ImmPRESS kit; Vector Labs) for 1 h at room
temperature. The slides were then washed using PBS 4  10 min
and the tissue sections were treated with DAB reagent to develop
colour as per the manufacturer’s instruction (DAB substrate kit;
Vector Labs) and the sections were counterstained with haematoxylin (Vectors Lab). Finally, the slides were washed in tap water
and were dehydrated in increasing grades of alcohol (20–100%),
and then washed with xylene for 5 min and dried at 37 1C. After air
drying, slides were mounted in paramount mounting medium
(Fisher Scientific, Fair Lawn, NJ, USA). Slides were observed
and photographs were taken using Nikon Eclipse E400 light
microscope (Kawasaki, Japan).
Immunohistochemistry scoring. Stained tissue arrays were
observed and graded by pathologist Dr Sonny L Johansson
at UNMC (Omaha, NE, USA). The grading of PP2A–A-, -B0 g-,
and -C-stained intensity was scored on a 0–3 þ scale and defined
as follows: 0, no staining; 1 þ , weakly positive; 2 þ , moderately
positive; and 3 þ , strongly positive. The percentage of the area
stained was based on: 0–25% ¼ 1, 26–50% ¼ 2, 51–75% ¼ 3, and
76–100% ¼ 4. The composite score is the product of the percentage
of positive cells per area and intensity of staining. The composite
score is used to define the positivity and negativity of staining. A
composite score of 0 is considered negative staining, whereas X1 is
positive staining. Photographs of the representative area were
taken.

RNA isolation and quantitative real-time PCR. Total RNA was
isolated using the Qiagen RNeasy mini kit (Qiagen, Valenica, CA,
USA). The concentration of RNA was determined using NanoDrop ND 1000 Spectrophotometer (Wilmington,DE,USA) and
cDNA was synthesised by reverse transcription as described
previously (Moniaux et al, 2008). Quantitative reverse transcription real-time PCR was carried out as described previously
(Rachagani et al, 2011). Real-time PCR assay was performed on
Roche Light Cycler 480 systems (Roche, Indianapolis, IN, USA).
The primer sequences were designed using the Primer 3 software
(Rozen and Skaletsky, 2000) and the sequences are given in
Table 1. Polymerase chain reaction was then performed in 10 ml
reaction containing 5 ml 2  SBYR Green Master Mix, 3.2 ml of
autoclaved nuclease free water, 1 ml diluted RT product (1 : 10),
and 0.2 ml each of forward and reverse primers (5 pmol) for all
three subunits. The amplification conditions used for all three
subunits were a two-step cyclic process (95 1C for 10 min, followed
by 45 cycles for 95 1C for 10 s, 60 1C for 10 s, and 72 1C for 10 s).
The real-time PCR reactions were performed in triplicate and
template controls were run for each assay under similar conditions.
b-Actin was used as an internal control. The fold change of PP2AA, -B0 g, and -C was calculated by Delta Delta CT method.
Protein isolation and western blot assay. Cells were washed two
times with PBS and lysed in RIPA buffer (Tris-HCl 0.25 M,
SDS 0.2%, pH 6.8, glycerol 20%, 1 mM NaF, 10 mM b-glycerol
phosphate, and 1 ml ml ÿ 1 protease inhibitor cock tail; SigmaAldrich Corp., St. Louis, MO, USA). Scraped lysate was passed
through a 25-G 7/8 needle and centrifuged at 4 1C for 25 min at
13 000 r.p.m. The protein concentration of each sample was
quantified by using the Bio-Rad DC Protein Assay kit (Bio-Rad
Laboratories, Hercules, CA, USA). Total proteins (40 mg) were
separated by 10% SDS–PAGE and transferred to polyvinylidene
difluoride (PVDF) membranes. Blocking was performed in 5% dry
milk in PBS for 2 h, and incubated with primary antibodies (at
1 : 1000 dilution) against PP2A-A, PP2A-B0 g, and PP2A-C) overnight, and then washed with PBST 4  10 min. The corresponding
secondary antibodies (at 1 : 2000 dilution) were added and incubated
at room temperature for 1 h. After washing with PBST 4  10 min,
the signals were detected using enhanced chemiluminence (ECL)
reagents and membranes were exposed to ECL-sensitive X-ray films
(Molecular Technologies, St.Louis, MI, USA).
Transfection of PCa cells with siRNA specific for PP2A-Aa. For
transient knockdown of PC-3, C-33 and C-81 PCa cells, we used
100 bp of siRNA oligonucleotides of human PP2A-Aa-specific
siRNA and SCR oligos using Lipofectamine 2000 transfection
reagent. Cells that have been transfected for 72 h were considered
for experimental studies such as migration assay and immunoblotting analysis. To demonstrate the effect of PP2A-Aa knockdown
on AKT phosphorylation, whole-cell lysates were collected for
further analysis after 72 h of transfection and proteins were
fractionated on 10% SDS–PAGE and blotted on PVDF membranes. Following blotting, membranes were probed with antibodies specific for PP2A-Aa, phospho-AKT, total AKT, active

Table 1. The oligonucleotide primers sequence used for detecting the expression of PP2A-C, -B0 g, and -Aa/b, in the RT–PCR analysis

Gene

Primer sequences

PP2A-C
0

Forward: 50 -TCGTTGTGGTAACCAAGCTG-30 Reverse: 50 -AACATGTGGCTCGCCTCTAC-30
0

0

0

PP2A-B g

Forward: 5 -ACAGTGAAGGACGAGGCTCA-3 Reverse: 5 -CTTCCAAGGCTTTCTTGGTG-3

PP2A-Aa/b

Forward: 50 -GCTTCAATGTGGCCAAGTCT-30 Reverse: 50 -GGTCCTGGGTCAGCTTCTCT-30

0

Amplified
length (bp)

Annealing
temperature (1C)

100

58

112

54

102

55

Abbreviations: PP2A ¼ protein phosphatase 2A; RT–PCR ¼ Real Time -polymerase chain reaction.
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b-catenin, phospho-FAK (Y576/577), and total FAK. The blots
were re-probed with b-actin antibody to confirm equal loading of
the samples in all the lanes.
Cell migration assays
Transwell migration and wound healing assay. Assays were
adapted with slight modification as described previously (Senapati
et al, 2010). For both procedures, PP2A-Aa knockdown PC-3 were
trypsinised and used to perform assays. First, to investigate the role
of PP2A-Aa in cell migration, we used Boyden chambers with
8-mm pore size. Transient knockdown of PC-3 cells were seeded at
the density of 1  105 cells per well in the upper chamber of the
insert, while the lower chamber was filled with 10% FBS, which is
used as a chemoattractant. After 24 h of incubation, the PC-3 cells
remaining above the insert membrane were removed by gentle
scraping with a sterile cotton swab. Cells that invaded through the
pores to the bottom of the insert were fixed and stained with crystal
violet for 10 min. Invading cells on representative sections
of each membrane were counted under light microscopy. Under
each experimental condition, the number of invading cells was
calculated as the percentage of invaded cells compared with the
SCR control cells. The experiment was performed in triplicate and
t-tests were used to determine the statistical significance in
migration between the SCR and knockdown cells. For wound
healing assay, post-transfected PC-3 cells were trypsinised,

A

RESULTS

Immunostaining of the scaffold subunit of PP2A-Aa/b in
benign and PCa tissues. The expression pattern of the PP2A-Aa/
b scaffold subunit in PCa and benign tissues was studied using
IHC. A total of 175 tissue spots were stained for PP2A-Aa/b,
among which 29 (n ¼ 29) were benign and 146 (n ¼ 146) were
cancer tissue spots. In benign prostate tissue, a strong expression of
PP2A-Aa/b in the epithelial cells was observed, while no staining
was observed in the surrounding stroma (Figure 1A). Out of the
146 total cancer tissues analysed, 12.3% (18 out of 146) were
positive for PP2A-Aa/b. In the benign tissue, 48.2% (14 out of 29)
were positive (Table 2). Protein phosphatase type 2A-Aa/b
exhibited both cytoplasmic and nuclear staining patterns and
immunohistological staining was stronger in benign tissues
compared with malignant tissues and the difference was

Benign

PP2A-Aa/!

3
2.5

×10
Benign prostate tissue ×40

2
1.5

Cancer

Mean (± s.e.) composite score

counted, and seeded at a density of 1  105 cells in 60-mm Petri
dishes with 10% RPMI, with and without knockdown of PP2A-Aa,
for 48 h. After overnight incubation and with 490% confluence, a
wound was induced with a sterile pipette tip. Images of wound
areas were randomly chosen and images were obtained at 0 and
12 h, and the motility of the cells was compared between the SCR
and knockdown cells.

1
P<0.001
0.5

***
×10

0
Benign

Cancer

Prostate cancer ×40

Fold change in PP2A-Aa
expression (a.u.)

B

1.2

C

P <0.01

P <0.001

PC3

PC3M

1

PP2A-Aa/!

0.8
!-Actin

0.6
0.4

LNCaP (C-33)

0.2

LNCaP (C-81)

PP2A-Aa/!
-8
1)
C

aP

(C

-3
3)

!-Actin

LN

LN

C

aP

(C

PC
3M

PC
3

0

Figure 1. Immunohistochemical, real-time PCR, and western blot analysis of the PP2A scaffold subunit (PP2A-Aa/b) in prostate tissues and
cancer cells. (A) The mean composite score is plotted and a significant (Po0.001) downregulation of the scaffold subunit (PP2A-Aa/b) was
observed in the prostate cancer tissues compared with benign prostatic tissue. The representative figure shows immunoreactivity of PP2A-Aa/b in
benign prostate and prostate cancer tissues. A distinct nuclear to diffused cytoplasmic staining was observed in benign tissue, whereas almost
no staining was observed in the cancerous prostate tissues (black arrows). (B) Real-time PCR analysis using primers specific for PP2A-Aa/b in
LNCaP C-33, C-81, PC-3, and PC-3M shows downregulation of PP2A-Aa/b in AI-LNCaP C-81 compared with AD-C-33 cells. Similarly, the
PC-3 cells show a higher expression of PP2A-Aa/b than in PC-3M. b-Actin was used as an internal control. (C) Western blot analysis shows
a decreased expression of PP2A-Aa/b in high metastatic cells (PC-3M, C-81) compared with low metastatic cells (PC-3, C-33).
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Table 2. Comparison of the composite scores for positivity and negativity of PP2A-C, -B0 g, and -Aa/b staining between benign prostatic tissue and
prostate cancer.

PP2A-B0 c

PP2A-C
Tissue
type

Pos.

Neg.

Total

P-value
(v2 test)

Pos.

Benign

28 (90.3%)

3 (9.7%)

31

0.6

10 (52.6%)

9 (47.4%)

Cancer

58 (90.6%)

6 (9.4%)

64

22 (13.4%)

141 (86.6%)

86

9

95

32

150

Neg.

PP2A-Aa/b

Total

P-value
(v2 test)

Pos.

Neg.

Total

P-value
(v2 test)

19

0.0002

14 (48.2%)

15 (51.8%)

29

o0.001

163

18 (12.3%)

128 (87.7%)

146

182

32

143

175

Abbreviations: Neg. ¼ negative; Pos. ¼ positive; PP2A ¼ protein phosphatase 2A.

statistically significant (P-value o0.001) between benign and
malignant prostate tissue (Figure 1A and Table 2). On the basis of
the staining analysis, we observed that there is a gradual loss of
PP2A-Aa/b expression during PCa pathogenesis, strongest being
in normal and benign and very weak expression in the cancer
tissue sections.
Expression of the PP2A-Aa/b scaffold subunit in low and high
metastatic PCa cells. Upon performing quantitative real-time
PCR, we observed that the expression of PP2A-Aa/b was
downregulated at the mRNA level (2.1-fold less) in the highly
metastatic PC-3M cells when compared with the low metastatic
PC-3 cells (Po0.01) (Figure 1B). Similar results were observed in
high metastatic LNCaP (C-81) cells as compared with low
metastatic LNCaP (C-33) cells (Po0.001). In the LNCaP (C-81)
cells, the PP2A-Aa/b was 2.8-fold less than the LNCaP (C-33) cells
(Figure 1B). At the protein level, both in the PC-3M and LNCaP
(C-81) cells, a significantly low expression of PP2A-Aa/b was
observed compared with PC-3 and LNCaP (C-33) cells, which
implies a downregulation of PP2A-Aa/b in androgen-insensitive
and highly metastatic PCa cells (Figure 1C).
Downregulation of PP2A-Aa/b scaffold subunit leads to
increase of phosphorylated Akt in PCa cells. On the basis of
the fact that AKT is one of the major substrate of PP2A and
AKT activation is dependent on the phosphorylation at serine
residue 473. We further assessed AKT phosphorylation in the low
metastatic PC-3 and high metastatic PC-3M cells, as well as in AD
LNCaP (C-33) and AI LNCaP (C-81) cells by western blotting.
Here, we compared the endogenous levels of phosphorylation on
serine 473 of AKT in relation to that of PP2A-Aa/b downregulation in PCa cells. Phosphorylation of AKT-Ser473 increases
in PC-3M and LNCaP (C-81) cells as compared with PC-3 and
LNCaP (C-33) cells (Supplementary Figure 1).
Immunohistochemistry of the regulatory subunit PP2A-B0 c in
benign and PCa tissues. In this analysis, 182 prostate tissue spots
were stained. Out of 163 cancer tissue spots, 13.4% (22 out of 163)
were positive for PP2A-B0 g, whereas 52.6% (10 out of 19) benign
tissue were positive (Figure 2A and Table 2). Localisation of PP2AB0 g was mostly in the nucleus and was also present in the
cytoplasm of epithelial cells. No expression of PP2A-B0 g was
observed in the surrounding stroma. Upon comparing prostatic
adenocarcinoma and benign prostatic tissue, the expression
of PP2A-B0 g was observed to be significantly decreased in the
adenocarcinoma tissues (P-value ¼ 0.0002), while it was uniformly
lost in the highly metastatic cancer cells (Figure 2A and Table 2).
Expression of the regulatory subunit PP2A-B0 c in PCa metastatic cells. Regulatory subunit PP2A-B0 g was significantly downregulated at both the transcript and protein levels in highly
metastatic PCa cells vs low metastatic PCa cells. The expression of
PP2A-B0 g mRNA was significantly low in LNCaP (C-81) cells
(3.33-fold less) when compared with LNCaP (C-33) cells
2594

(Po0.05). In the PC-3 model, PC-3M cells (highly metastatic)
had 1.5-fold less expression of PP2A-B0 g mRNA than in PC-3 cells
(low metastatic) (Figure 2B) (P ¼ 0.6). At the protein level, the
expression of PP2A-B0 g was low in the highly metastatic PC-3M
and LNCaP (C-81) cells when compared with low metastatic PC-3
and LNCaP (C-33) cells (Figure 2C), indicating a gradual loss of
PP2A-B0 g expression with the progression of PCa.
Immunoreactivity of PP2A-C catalytic subunit in benign and
malignant PCa tissue sample. We demonstrated PP2A-C expression pattern in benign prostatic hyperplasia (BPH) and PCa tissue
sample by performing IHC on commercially available PCa tissue
microarrays. We screened a total of 95 tissue spots where 64 spots
were malignant and 31 were benign (BPH) spots. Protein
phosphatase type 2A-C was equally expressed in both BPH and
cancer (Figure 3A and Table 2). With respect to localisation,
PP2A-C was primarily expressed in the cytoplasm and the nucleus
(Figure 3A). The positivity of PP2A-C expression in BPH/benign
and malignant tissues were 90.3% (28 out of 31) and 90.6% (58 out
of 64), respectively, and the difference was not statistically
significant (P-value ¼ 0.6) (Figure 3A and Table 2).
Expression of PP2A-C at mRNA and protein levels. In addition
to performing immunohistochemical analysis in various premalignant and malignant PCa tissues, the expression pattern of
PP2A-C was analysed at the mRNA and protein levels in PC-3
(low and high metastatic cell lines) and LNCaP (C-33 and C-81)
PCa cell line models. For quantitative analysis, PP2A-C expression
at the mRNA level was assessed by real-time PCR, where both
PC-3 and PC-3M cells had comparable expression (P ¼ 0.3) with
nonsignificant P-value and a similar expression pattern was
obtained in LNCaP C-33 (AD) and LNCaP C-81 (AI) cell lines
(Figure 3B) (P ¼ 0.9). Western blot studies further confirmed the
mRNA expression pattern, as there was no difference in the level of
PP2A-C protein between LNCaP (C-33) and LNCaP (C-81) cells,
as well as between PC-3 and PC-3M cells (Figure 3C). Thus, the
expression of PP2A-C is constant at both the mRNA and protein
levels in those paired cell lines.
Effects of transient knockdown of PP2A-Aa on Akt signalling
and invasive potential of PCa cells. By extending our previous
observation on the scaffold subunit, two siRNA oligos against the
PP2A-Aa were used for transient knockdown of PP2A-Aa in PC-3
and LNCaP cells. Scramble oligo-transfected cells were used as a
control. Lysates were collected and probed with the respective
antibodies. We looked at the impact of PP2A-Aa knockdown on
the activity and protein levels of Akt, b-catenin, and FAK protein
levels in PC-3 cells. As a result, the transient knockdown of PP2AAa in PCa cells led to a remarkable increase in the level of
phospho-Akt, active b-catenin, and phospho-FAK compared with
the SCR siRNA-transfected control (Figure 4A). Similar results
were also demonstrated in LNCaP (C-33 and C-81) cell line model
system, which showed that transient knockdown of PP2A-Aa
www.bjcancer.com | DOI:10.1038/bjc.2013.160
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Figure 2. Protein phosphatase 2A regulatory subunit (PP2A-B0 c) expression pattern in benign and prostate cancer tissues and cell lines.
(A) Immunohistochemical analysis of PP2A regulatory subunit (PP2A-B0 g) in benign and prostate cancer tissues. The mean composite score shows
statistically significant (Po0.001) downregulation of the regulatory subunit (PP2A-B0 g) in prostate cancer tissues compared with benign prostatic
tissue. Representative tissue spots show prominent nuclear and cytoplasmic staining in benign tissue, whereas almost no staining was observed in
the cancerous tissue (black arrows). (B) Quantitative real-time RT–PCR shows that regulatory (PP2A-B0 g) subunit mRNA was significantly
downregulated in AI LNCaP (C-81) PCa cells compared with AD LNCaP (C-33) PCa cells in the LNCaP model. No significant downregulation of
PP2A-B0 g mRNA was observed between PC-3 and its metastatic variant PC-3M cells. b-Actin was used as an internal control. (C) Immunoblotting
analysis shows a significant decrease of PP2A-B0 g protein in LNCaP (C-81) and PC-3M cells compared with LNCaP (C-33) and PC-3 cells,
respectively. b-Actin was used as loading control.

resulted in enhanced AKT-Ser473 phosphorylation with no change
in the total AKT levels (Supplementary Figures 2 and 3).
To investigate the effect of PP2A-Aa on cell motility, migration
and wound healing assays were performed in PC-3 cells in which
PP2A-Aa was transiently knocked down for 48 h. As shown in
Figure 4B, the migration potential of PP2A-Aa knockdown
cells significantly increased at 24 h in transwell migration assay.
Similarly, quantification of the migration distance from wound
healing assays showed that wound closure in PP2A-Aa knockdown
cells was significantly higher than the control cells transfected with
SCR siRNA (Figure 4C). These results indicate that specific
knockdown of PP2A-Aa results in increased migration and
motility property of PCa cells.

DISCUSSION

It has been postulated that phosphorylation and dephosphorylation are coordinated events that are governed and balanced by the
activity of kinases and phosphatases (Bononi et al, 2011). Protein
phosphatase type 2A is a ubiquitously expressed serine/threonine
www.bjcancer.com | DOI:10.1038/bjc.2013.160

phosphatase, which acts as key dephosphorylating enzyme for
various signal-transduction pathways in eukaryotic cells (Millward
et al, 1999). Although numerous studies have shown the role of
PP2A as a tumour suppressor, the regulatory role of individual
subunits, which is deregulated in cancer, remains to be defined.
Recent evidence from the genomic and proteomic data clearly
defines the critical role of PP2A subunits under both normal
physiological and oncogenic conditions by regulating particular
substrates (Muneer et al, 2002; Sablina et al, 2007). Further,
because of the existence of several isoforms for each subunit, their
ability to form a variety of heterotrimers (70 different forms) could
explain the diversity of the PP2A holoenzyme complex and its
functional distinction (Janssens and Goris, 2001; Mumby, 2007;
Janssens et al, 2008). Thus, decreased activity of any of these
subunits might contribute to the proliferation of cancer cells. This
study focuses on the differential expression of various PP2A
subunits in benign and malignant prostatic tissues as well as how
this differential expression favours proliferation in the PCa cell
model system. To study the specific role of various subunits of
PP2A, we have compared the differential expression pattern of
PP2A-Aa/b, -B0 g, and -C in benign prostatic tissue and malignant
PCa tissue spots on a prostate TMA and in the clinically relevant
2595
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Figure 3. Expression of PP2A catalytic subunit (PP2AC) in benign and prostate cancer tissues and cell lines. (A) Immunohistochemical analysis of
PP2AC staining between benign and prostate cancer did not show any significant difference using a composite score method. Representative
images of prostate tissues stained for PP2AC show cytoplasmic and nuclear staining (black arrows) in both BPH and prostate tumour. (B) Real-time
PCR-based measurement of PP2A catalytic (PP2AC) subunit in prostate cancer cells. Expression of PP2AC at the transcript level is similar in both
the prostate cancer cell models (PC-3 and LNCaP). (C) Western blot analysis showing an equal expression of PP2AC in both the prostate cancer cell
model systems (PC-3 and LNCaP cells) and b-actin was used as loading control.

PCa cell model system PC-3 and LNCaP cells, to explore the
mechanism in both the AD and the AI status of PCa.
Previous work in various cancers such as breast, lung, and colon
have shown that the cancer-derived mutant form PPP2R1B (PP2A
structural subunit) may have an impaired function because of its
inability to form a complex with the catalytic and regulatory
subunits (Calin et al, 2000; Ruediger et al, 2001; Tamaki et al,
2004). Furthermore, Sablina et al (2007) have reported that the loss
of the PP2A-A (scaffold) subunit can induce oncogenic transformation through activation of small GTPase RalA (Sablina et al,
2007). In our study, we observed a statistically significant reduction
of the PP2A-Aa/b scaffold subunit in cancer specimens when
compared with benign tissues. Similarly, the endogenous level of
PP2A-Aa at both the protein and mRNA levels were significantly
downregulated in C-33 and PC-3 cells as compared with C-81 and
PC-3M high metastatic cell lines. Therefore, our study is in support
of the somatic mutations of the PP2A-Aa and -b subunits observed
in colon, breast, and lung cancers, stating that alterations or loss of
any of PP2A-Aa and -b subunits can lead to an inhibitory effect by
interfering with the interaction of the PP2A scaffold subunit and
the PP2A catalytic subunit or regulatory subunit (Calin et al, 2000;
Takagi et al, 2000; Tamaki et al, 2004). Also, earlier reports indicate
that the loss of expression of the PP2A structural subunit may be
an important factor for the failure of integrin dephosphorylation in
breast cancer cells (Suzuki and Takahashi, 2003).
Second, we looked at the possible involvement of the regulatory
(B) subunit in both tissues as well as in the cell line model systems.
2596

Previous reports from many researchers have provided their
ideology of PP2A interacting with small t (SV40 small t-antigen)
protein, implying that small t might be directly interacting with the
dimer or it displaces the third regulatory subunit from the
holoenzyme complex. Among the PP2A-B family members, B56
or B0 will participate in several regulating mechanisms, such as
signalling, cell cycle check point, development, and apoptosis
(Seeling et al, 1999; Li et al, 2002; Yang et al, 2003; Chen et al,
2004; Van Kanegan et al, 2005; Margolis et al, 2006). Studies from
Chen et al (2004) have provided evidence that suppressing B56g
seemed to mimic the ST-induced cell transformation, rather than
the B55 regulatory subunit, thus inhibiting the PP2A-specific
phosphatase activity (Chen et al, 2004). Our results show that
immunohistochemical expression for the PP2A-B0 g subunit
displayed a higher expression in benign tissues as compared
with the malignant prostate tissue. Similarly, the mRNA and the
endogenous level of the PP2A-B0 g subunit was strongly expressed
in both AD C-33 and PC-3 (AI) cells when compared with AI C-81
and high metastatic PC-3M cells. This finding is consistent with
the observation of Sablina et al (2010), who demonstrated that the
suppression of specific regulatory subunits B56a, B56g, and PR72/
130, as well as PTPA, induced a transformed phenotype,
implicating their role in cell transformation. Also, it is suggested
that PP2A-B0 g was involved in the regulation of WNT signalling by
interacting with APC tumour suppressor protein, thereby interfering with the APC–Axin complex formation, which may have a
destabilising effect on b-catenin, and thus indirectly prevent
www.bjcancer.com | DOI:10.1038/bjc.2013.160
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Figure 4. Effect of transient knockdown of PP2A-Aa on Akt, b-catenin, and FAK signalling and cell motility assays in prostate cancer (PC) cells.
(A) Upon knockdown of PP2A-Aa, phosphorylation of AKT-Ser473 in PC-3 cells was increased. In addition, immunoblot analysis of PC-3 cells
demonstrates increased phosphorylation of FAK-Tyr576/577 along with b-catenin activation after transient knockdown of PP2A-Aa. (B) Also, the
migration potential of PC cells was increased after transient knockdown of PP2A-Aa at 48 h. Cells that are migrated through the 8-mm pores of a
polyethylene terephthalate (PET) membrane were quantified in 10 random fields and plotted. (C) Protein phosphatase type 2A-Aa was transiently
knocked down in PC-3 PC cells and grown for 48 h. Cells were then trypsinised and reseeded at the cell density of 1  105 per plate. PC-3 PC cells
were grown until they achieved a confluent monolayer and a scratch was made using a sterile pipette tip. Introduced wounds were photographed
at 0 and 12 h. The distance migrated by the PC-3 cells were quantified by measuring the distance migrated from the 0 to 12 h. Thus, the knock
down of the scaffold subunit (PP2A-Aa) demonstrated the increasing metastatic potential as a consequence of reduced levels. Thus, western blot
analysis showing that phospho (p)-Akt, active b-catenin, and phospho-FAK protein levels directly correlates with cell survival, proliferative capacity,
and invasive potential of PC cells but no change in the respective total proteins. Furthermore, the cell motility analysis through transwell migration
and wound closure analysis on PC-3 cells after transient knockdown of PP2A-Aa at 48 h suggests that the knockdown of PP2A-Aa may have a role
in increased migration capacity of PC cells.

transcriptional activation of b-catenin target genes such as
MYC (c-myc) and CCND1 (Cyclin D1) (Seeling et al, 1999).
The alteration/loss of expression of PP2A-B0 g observed in our
study may contribute to enhanced b-catenin activation, leading to
the transcription of b-catenin into the nucleus and resulting in
malignant transformation. Further, Li et al (2007) was the
first to report that specific regulatory subunit B56g-containing
complexes of PP2A function as tumour suppressors by dephosphorylating p53 at Thr55, which further leads to p53 degradation.
Specifically, these reports suggest that the loss of B56g subunit
www.bjcancer.com | DOI:10.1038/bjc.2013.160

expression would result in a loss of PP2A phosphatase activity and
thereby induce cellular transformation (Li et al, 2007).
In our earlier study, we have demonstrated that PPP2CA, which
encodes for the catalytic subunit (a-isoform) of the PP2A-C, was
found to be downregulated in AI PCa cell line as compared with
AD (Singh et al, 2008). In addition, Prowatke et al (2007) also
showed the downregulation of the b-isoform of the PP2A catalytic
subunit in prostate carcinoma using TMA (Prowatke et al, 2007).
In the present communication, we have demonstrated that there
was no significant difference in the expression of PP2A-C between
2597
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the level of AKT phosphorylation and the loss of expression of
endogenous levels of the PP2A-Aa subunit. This implies that the
loss of expression or suppression of the PP2A scaffold subunit may
contribute to the activation of the PI-3 kinase/AKT pathway and
thus initiate oncogenesis and transformation of benign cells into
PCa cells. We believe that alterations in the level of PP2A catalytic
or the regulatory subunit in PCa cells may be critical in regulating
the downstream targets (Seeling et al, 1999; Suzuki and Takahashi,
2003; Margolis et al, 2006; Li et al, 2007; Bhardwaj et al, 2011).
The influence of PP2A on cellular dynamics such as cell adhesion,
migration, and cytoskeleton dynamics were poorly understood.
A series of events such as lamellipodium formation, actin-rich
extension (filopodia), and focal adhesion formation are indicative
of cellular migration (Ross et al, 2012). Protein phosphatase 2A has
been shown to colocalise with b1-integrin, which is required for
FAK regulation (Young et al, 2002, 2003). Our studies corroborate
earlier findings, which have demonstrated that PP2A inhibition
resulted in enhanced hyperphosphorylation of FAK leading to
cellular migration, enhanced motility, and cellular spreading
activity (Slack et al, 2001; Young et al, 2002). These observations
were substantially demonstrated in BL6 mouse melanoma cells,
head and neck cancer, lung cancer, and other malignancies
(Jackson et al, 1997; Meisinger et al, 1997; Ito et al, 2000). The data
obtained in our study demonstrate that downregulation of PP2A
scaffold subunit in PCa cells leads to enhanced cell spreading,
migration, survival signaling, and increased viability. Furthermore,
the FAK activation in the phospho-form of Y576/577 will define
the crucial role of PP2A in adhesion and migration. In addition,
the role of PP2A scaffold subunit in cellular communication can be
evidenced by active b-catenin expression. Taken together, the
results revealed the mechanistic insight into the functional role of
PP2A subunit, specifically the scaffold subunit in promoting
progression to androgen independence. Thus, PP2A is likely to

Loss of PP2A-Aa/!
expression/
haploinsufficiency/function

B′"

benign and PCa tissue spots, with regard to AD and AI
cells (LNCaP) and between low metastatic and high metastatic
(PC-3 and PC-3M) cells both at the protein and mRNA levels. The
available oncomine data in gastric cancer also supports that the
equal existence of catalytic subunit (remained unchanged) in both
normal and cancerous tissues. Although there was a slight
difference in the PP2A-C expression pattern between benign and
malignant prostate tissues, the difference was statistically insignificant. The results in this study support the notion that the
synergistic involvement of the catalytic, regulatory, and scaffold
subunits are required for the entire phosphatase activity of
PP2A. This study supports the mechanism of autoregulation of
PP2A (Baharians and Schonthal, 1998), which exerts a constant
level of PP2A-C nonspecific expression in tissues that are
independent of hormone status. Early investigations demonstrated
that post-translational modification of PP2A catalytic subunit
modified by methylation or phosphorylation (at tyrosine and
threonine residues) is a crucial determinant for PP2A regulation
and holoenzyme complex formation. These modification are
governed by leucine carboxyl methyltransferase 1 and phosphatase
methyl esterase. Like the catalytic subunit, the regulatory subunit of
PP2A PR61/B0 is also subjected to post-translational modification
(phosphorylation) (Longin et al, 2008). However, this modification
is a context-dependent process. Serine or proline phosphorylation
of PR61/B0 subunit by ERK would lead to its dissociation from the
catalytic or holoenzyme complex (Letourneux et al, 2006; Cho and
Xu, 2007). In contrast, phosphorylation of PR61/B0 subunit
at serine 37 by Chk1 would specifically favour formation
of holoenzyme complex assembly (Margolis et al, 2006). Thus, in
the holoenzyme regulation apart from the catalytic subunit posttranslational modifications of the other regulatory and scaffold
subunits are equally important.
Finally, it is now well established that deregulation of PP2A
signalling is considered to be a prerequisite for the development of
malignant cells. More recently, it has been demonstrated that
inhibition of PP2A activity leads to proliferation and survival of AI
PCa cells through activation of AKT and ERK signalling (Bhardwaj
et al, 2011). In addition, the direct evidence of PP2A as a tumour
suppressor has been shown in a knock-in and knockout mouse
model expressing E64D and E64G mutations (Ruediger et al,
2011). However, little is known about the nature of phosphosignalling networks associated with this malignant transformation
of prostate (Westermarck and Hahn, 2008). Moreover, the
enzymatic activity of a protein can be altered by reversible
phosphorylation (Nolan et al, 1964). Considering the distinct role
of PP2A, which can regulate the phosphorylation of particular
substrates involved in neoplastic transformation, further work was
extended in the expressional analysis of the phosphorylation status
of one of the PP2A substrate AKTs. The role of PP2A as a major
negative regulator of the AKT pathway is well established in PCa
(Li et al, 2005). Previous work has shown that the partial
suppression of the endogenous Aa subunit leads to the activation
of the AKT kinase (Chen et al, 2005). Furthermore, hyperactivation of AKT signalling has been shown in prostate cells as well as in
advanced PCa tissues (Kreisberg et al, 2004). To determine
whether the AKT pathway was altered in PCa (in vitro),
we transiently knocked down PP2A-Aa in PC-3 and C-33 cells
for 48 h. We found that transient knockdown of PP2A-Aa in PC-3
and C-33 cells produced a more significant increase in the
phosphorylated AKT level at the serine 473 residue as compared
with the SCR-transfected control cells. In addition, through
functional analysis, we observed a knock down of the scaffold
subunit using PP2A-Aa siRNA or antisense oligodeoxynucleotides,
which significantly enhanced cell migration and invasion in PC-3
cell line. Our results imply the direct involvement of PP2A
subunits in regulating growth and proliferation of AI PCa cells.
Moreover, we observed that there is a perfect correlation between
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Figure 5. Diagrammatic representation of the loss of PP2A subunits in
prostate cancer pathogenesis. Schematic representation of loss/
reduced expression levels of the scaffold subunit (PP2A-Aa/b) and the
regulatory subunit (PP2A-B0 g), thereby leading to the disruption of
heterotrimeric complex formation and impaired substrate specificity.
Thus, the regulatory and scaffold subunit of PP2A may have a role in
prostate cancer progression. Mechanistically, transient knockdown of
PP2A-Aa leads to increased phospho-AKT level in prostate cancer cells.
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play an integral role in tumour suppressor network, which is
partially regulated by AKT/FAK/b-catenin in promoting AI
growth of PCa.
In conclusion, based on our studies we report that the
expression of the PP2A was downregulated during PCa progression primarily due to the downregulation of the regulatory and
scaffold subunits and not the catalytic subunit. The downregulation of the scaffold subunit further emphasises the fact that
it was unable to organise both the regulatory and catalytic subunit
together for its functional role of cellular transformation (Figure 5).
Further, based on this study, it is very clear that even if there is no
change in the constitutive expressional level of the C subunit, a
differential expression or loss of expression on A and B subunits
may have an influential role in PCa progression. Thus, this study
on the downregulation of the PP2A subunits has a critical role
in PCa pathogenesis and progression.
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